Abbott under investigation for stent sales, marketing
Device Regulation Alert: Safety, Compliance and Reimbursement News, August 4, 2008
The Department of Justice (DOJ) is investigating Abbott Laboratories’ sales and marketing practices for its bile-duct stents, the company reported in its quarterly filing with the Securities and Exchange Commission.
The DOJ is trying to determine whether Abbott violated the Federal False Claims Act, the Food, Drug, and Cosmetic Act, and the Anti-kickback Statute in connection with Medicare and/or Medicaid reimbursement paid to third parties.
Boston Scientific revealed in February that the DOJ was investigating whether it and other suppliers are illegally marketing the stents for unapproved uses.
Comments
0 comments on “Abbott under investigation for stent sales, marketing ”
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Big Pharma Performance Before, During and Beyond the Global Recession
This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global...
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Topic: CMS, OESS post new security compliance review information, checklist
- What does case-mix index mean to you?
- QA:Coding multiple initial infusions
- Capturing all necessary codes for IUD insertion and removal can be challenging
- News and briefs: Oklahoma Osteopathic Association against residency bill change
- OB services: Coding inside and outside of the package
- HIPAA Q&A: Level of encryption needed for email
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- New conflicts of interest create new challenges
- Joint Commission Center announces handoff communication solutions
- Inside best practice: Reduce patient falls with a stoplight
- Identify modifiable risk factors to prevent patient falls
- Hospitalist-surgeon comanagement has no effect on outcomes
- HIPAA Q&A: Level of encryption needed for email
- Case Management Monthly, June 2012
- Searched